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M
ultiple randomized controlled trials showed high recanalization rates and good functional outcome in patients with acute ischemic stroke using the combination of IV rtPA (recombinant tissue-type plasminogen activator) and mechanical thrombectomy (MT) or MT alone. 1 Reperfusion therapies, however, are associated with the risk of intracranial hemorrhage (ICH). In recent years, the general approach of reporting symptomatic ICHs (SICH) was to use the ECASS (European Cooperative Acute Stroke Study) II/III classification. 2, 3 At a consensus meeting of leading stroke researchers in 2015, a new classification for ICHs, the Heidelberg Bleeding Classification (HBC), was suggested. 4 The proposed classification should bring considerable benefits to formally categorize ICHs in clinical trials because of more precise anatomic description and better assessment of ICHs being symptomatic.
Because different classifications might result in a varying number or frequency of reported incidents 5 and therefore could affect interpretation and comparison of data, the purpose of this analysis was to compare the generally used ECASS III classification with the HBC in patients with postprocedural ICHs after endovascular stroke treatment.
Methods
From a prospectively compiled database of a tertiary care university hospital with stroke center and permanent neurointerventional attendance, we selected consecutive patients with acute ischemic stroke caused by a large vessel occlusion in the anterior circulation in the period between February 2011 and March 2016. Patients were treated with MT and, if eligible, additionally IV rtPA. Follow-up brain imaging with computed tomography was performed within 18 to 36 hours and reviewed independently by neuroradiology staff (U.N. and J.P.) blinded to clinical, angiographic, and outcome data. Reported ICHs were categorized according to ECASS III 3 and HBC 4 classifications. In case of discrepancy, consensus was reached with additional neuroradiology staff members (M.A.M. and C.H.). ICHs were furthermore classified as SICH or asymptomatic intracranial hemorrhage (see online-only Data Supplement). Relatedness of neurological deterioration to the image findings was assessed by reviewing clinical data (eg, medical records; U.N., J.P., and C.U.). The stroke database was approved by the local ethics committee. Because of its retrospective character, additional written informed consent was waived by the ethics committee for this study. 
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Discussion
Our findings demonstrate that the overall number of classifiable postprocedural ICHs after acute ischemic stroke treatment differ considerably depending on the used classification.
HBC obviously offers a more thorough approach to categorize bleedings, with considering every possible type of hemorrhage. 4 After this new approach, additional 55 ICHs (35.3%) could be categorized properly. Of these additionally classifiable bleedings, however, only one ICH was classified as symptomatic according to HBC criteria. 4 In this particular patient, a periprocedural vessel perforation of the middle cerebral artery caused a lethal subarachnoid hemorrhage. Although subarachnoid hemorrhages after MT have been reported in ≤12.6% to 14.1% of treated patients, they usually have a benign course and are rarely symptomatic. 6 A meta-analysis of 5 randomized trials in patients with acute ischemic stroke showed an occurrence of 4.4% SICH in patients, who received MT. 1 Our total rate of SICH is comparable with 3.8% with HBC and 3.6% with ECASS III.
The differences between HBC and ECASS III classification-that is, the larger overall number of classifiable ICHs and the adjusted, perhaps even more specific criteria for SICH in HBC-will increase the reported number of hemorrhages and decrease the ratio of SICH with regard to asymptomatic intracranial hemorrhage when using HBC. On the contrary, because additionally assignable ICH could be symptomatic, using HBC might increase the total number of reported SICH for all treated patients. This potential discrepancy of reported numbers of SICH and asymptomatic intracranial hemorrhage needs to be considered when comparing scientific data. Conclusions in scientific articles should, thus, be related to the applied classification. 
Conclusions
The recently proposed HBC improves the ECASS III classification for ICHs after reperfusion therapy in acute ischemic stroke by (1) including previously nonclassifiable hemorrhages and (2) providing a formal approach for categorizing those hemorrhages. Future studies may benefit from the advantages of this classification.
It remains important to take into account the differences between HBC and older classifications, when comparing the rate of SICH of different trials.
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